SCHEMBL6415787

SCHEMBL6415787

CC(C)(C)NC(=O)c1cc(F)c(F)cc1F

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.71
APEX1 P27695 1/20 0.71
ANO1 Q5XXA6 2/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
ALOX5AP P20292 3/20 0.39
FEN1 P39748 3/20 0.39
ALPL P05186 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13152424 0.83 POLB (0.65) POLBAPEX1ANO1MAOAMAOB
SCHEMBL6415236 0.82 POLB (0.50) POLBAPEX1CYP11B1CYP11B2
SCHEMBL6419619 0.79 POLB (0.56) POLBAPEX1ALOX5APFEN1MAPT
SCHEMBL6419670 0.79 POLB (0.56) POLBAPEX1ANO1MAOAMAOB
SCHEMBL12121090 0.78 POLB (0.54) POLBAPEX1ANO1MAOAMAOB
SCHEMBL7981477 0.77 GAA (0.55) POLBAPEX1CYP11B1CYP11B2HTT
SCHEMBL13377324 0.77 POLB (0.53) POLBAPEX1ANO1MAOAMAOB
SCHEMBL6415657 0.77 POLB (0.61) POLBAPEX1ANO1CYP11B2ALPL
SCHEMBL506513 0.77 DGAT1 (0.54) POLBAPEX1MAOAMAOBMEN1
SCHEMBL24799394 0.75 ANO1 (0.54) POLBAPEX1ANO1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936736-B2 Amide derivative SUMITOMO MANUFACTURING COMPANY LIMITED (JP) 2005-08-30 US disclosed
EP-1034783-B1 AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS SUMITOMO PHARMA (JP) 2004-12-15 EP disclosed
US-20020147204-A1 Amide derivative SUMITOMO PHARMACEUTICALS COMPANY, LIMITED 2002-10-10 US disclosed
US-6384033-B1 DRUGS FOR VISION DEFECTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-07 US disclosed
EP-1034783-A1 AMIDE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147204-A1 Amide derivative ALDH1A2, NR1H2, HDAC3 POLB 3216/4885APEX1 1777/4885ANO1 3084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.